Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The phosphatase of regenerating liver (PRL) family, including PRL-1, PRL-2, and PRL-3, are prenylated phosphatases implicated as cancer biomarkers.
• While PRL-1 and PRL-3 functions are documented, the biological roles of PRL-2 in cancer remain largely uncharacterized.

Purpose of the Study:

• To investigate the role of PRL-2 in the migration and invasion of human cancer cells.
• To elucidate the signaling pathways modulated by PRL-2 in cancer progression.

Main Methods:

• PRL-2 expression analysis in human lung cancer cells (A549) and normal lung cells.
• PRL-2 knockdown using RNA interference (siRNA) and rescue experiments with siRNA-resistant vectors.
• Analysis of key signaling molecules including p130Cas, vinculin, ERK, ezrin, p53, Akt, and c-Src phosphorylation.
• Expression of wild-type and mutant PRL-2 (catalytic inactive and prenylation-deficient) to assess functional requirements.

Main Results:

• Human lung cancer cells, including A549, exhibit PRL-2 overexpression compared to normal cells.
• PRL-2 knockdown significantly inhibited cell migration and invasion, which was reversible by expressing siRNA-resistant PRL-2.
• PRL-2 suppression decreased p130Cas and vinculin expression, reduced ERK phosphorylation, and increased ezrin phosphorylation.
• PRL-2's catalytic activity and prenylation site are essential for its function in promoting cell migration and invasion.
• Wild-type PRL-2, but not mutants, induced ERK phosphorylation and nuclear translocation.

Conclusions:

• PRL-2 plays a critical role in promoting human cancer cell migration and invasion.
• PRL-2 exerts its function through a Src-independent p130Cas signaling pathway and an ERK-dependent mechanism.
• PRL-2 is a potential therapeutic target for inhibiting cancer metastasis.